DARE
HEALTHCAREDare Bioscience Inc
$3.16-0.11 (-3.36%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DARE Today?
No stock-specific AI insight has been generated for DARE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.27$3.78
$3.16
Fundamentals
Market Cap$46M
P/E Ratio—
EPS$-1.20
Dividend Yield—
Dividend / Share—
ROE-25.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding14.6M
DARE News
20 articles- Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026Yahoo Finance·May 7, 2026
- Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 26, 2026
- Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 26, 2026
- On National Viagra Day, Women Finally Claim Their Turn:Yahoo Finance·Mar 23, 2026
- Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026Yahoo Finance·Mar 20, 2026
- Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm BirthYahoo Finance·Mar 16, 2026
- Daré Bioscience Participates in Virtual Investor “What This Means” SegmentYahoo Finance·Mar 12, 2026
- Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 9, 2026
- uniQure (QURE) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 2, 2026
- Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerYahoo Finance·Feb 23, 2026
- Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for WomenYahoo Finance·Feb 11, 2026
- Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In GrowthYahoo Finance·Jan 20, 2026
- DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing FacilityYahoo Finance·Dec 10, 2025
- Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-MaximizationYahoo Finance·Dec 1, 2025
- Daré Bioscience Receives $3.6 Million in Additional Grant FundingYahoo Finance·Nov 24, 2025
- Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...Yahoo Finance·Nov 14, 2025
- Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 13, 2025
- Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 12, 2025
- Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual HealthYahoo Finance·Nov 11, 2025
All 20 articles loaded
Price Data
Open$3.37
Previous Close$3.27
Day High$3.40
Day Low$2.89
52 Week High$3.78
52 Week Low$1.27
52-Week Range
$1.27$3.78
$3.16
Fundamentals
Market Cap$46M
P/E Ratio—
EPS$-1.20
Dividend Yield—
Dividend / Share—
ROE-25.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding14.6M
About Dare Bioscience Inc
Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—